A Look at Teva Pharmaceutical’s Valuation Multiples in June
On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x. The company’s forward EV-to-EBITDA, which is a capital structure–neutral valuation measure, is 11.2x. This multiple is higher than the industry average of 10.3x.